This study lays the groundwork to robustly assess additional heterogeneity within Grp3 and Grp4 medulloblastoma, to define its biological and clinical relevance, and to exploit these in improved therapeutic approaches. This evidence concerns the gene RASGRP3 and medulloblastoma.